| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Galdiero, R Pivonello, L F S Grasso, A Cozzolino, A Cola. Growth hormone, prolactin, and sexuality. Journal of endocrinological investigation. vol 35. issue 8. 2013-03-07. PMID:23014134. |
sexual function in men and women with gh deficiency (ghd) and gh excess, particularly in acromegaly, is scantily studied and gh- or igf-i-dependent effects are difficult to quantify. |
2013-03-07 |
2023-08-12 |
Not clear |
| M Galdiero, R Pivonello, L F S Grasso, A Cozzolino, A Cola. Growth hormone, prolactin, and sexuality. Journal of endocrinological investigation. vol 35. issue 8. 2013-03-07. PMID:23014134. |
data on beneficial effects of gh replacement therapy and specific surgical or pharmacological approach for acromegaly are far to be fully elucidated although restoring normal gh/igf-i levels have been associated to improvement of sexual function. |
2013-03-07 |
2023-08-12 |
Not clear |
| Yusuf Aydın, Hülya Coşkun, Seher Kır, Selma Yazici, Özlem Kudaş, Adem Güngö. Rheumatoid arthritis masquerading as acromegaly recurrence: report of two cases. Rheumatology international. vol 32. issue 9. 2013-03-01. PMID:20369240. |
acromegaly is a chronic endocrinopathy characterized by hypersecretion of growth hormone (gh) and consequently of insulin-like growth factor-1 (igf-1). |
2013-03-01 |
2023-08-12 |
Not clear |
| Yusuf Aydın, Hülya Coşkun, Seher Kır, Selma Yazici, Özlem Kudaş, Adem Güngö. Rheumatoid arthritis masquerading as acromegaly recurrence: report of two cases. Rheumatology international. vol 32. issue 9. 2013-03-01. PMID:20369240. |
after excluding the acromegaly activation and arthropathy by gh and igf-1 measurement, according to clinical presentation, laboratory and radiological assessments, patients were diagnosed as ra. |
2013-03-01 |
2023-08-12 |
Not clear |
| Rajat Kumar Das, Sarmistha Banerjee, Bernard H Shapir. Noncanonical suppression of GH-dependent isoforms of cytochrome P450 by the somatostatin analog octreotide. The Journal of endocrinology. vol 216. issue 1. 2013-03-01. PMID:23077183. |
octreotide is a potent somatostatin analog therapeutically used to treat several conditions including hyper gh secretion in patients with acromegaly. |
2013-03-01 |
2023-08-12 |
human |
| Antônio Ribeiro-Oliveira, Ariel Barka. The changing face of acromegaly--advances in diagnosis and treatment. Nature reviews. Endocrinology. vol 8. issue 10. 2013-02-06. PMID:22733271. |
acromegaly is a chronic disease characterized by the presence of a pituitary growth hormone (gh)-producing tumour, excessive secretion of growth hormone, raised levels of insulin-like growth factor i (igf-i) and characteristic clinical presentation of acral enlargement. |
2013-02-06 |
2023-08-12 |
Not clear |
| Antônio Ribeiro-Oliveira, Ariel Barka. The changing face of acromegaly--advances in diagnosis and treatment. Nature reviews. Endocrinology. vol 8. issue 10. 2013-02-06. PMID:22733271. |
over the past two decades, major advances have occurred in the understanding of some aspects of acromegaly--such as the biology of pituitary tumours, the physiology, molecular mechanisms of gh secretion and igf-i generation, and the pathogenesis of comorbidities. |
2013-02-06 |
2023-08-12 |
Not clear |
| L Boero, M Manavela, T Meroño, P Maidana, L Gómez Rosso, F Brite. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clinical endocrinology. vol 77. issue 4. 2013-02-04. PMID:22510144. |
gh levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. |
2013-02-04 |
2023-08-12 |
Not clear |
| L Boero, M Manavela, T Meroño, P Maidana, L Gómez Rosso, F Brite. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clinical endocrinology. vol 77. issue 4. 2013-02-04. PMID:22510144. |
acromegaly is characterized by gh excess and insulin resistance. |
2013-02-04 |
2023-08-12 |
Not clear |
| David D W Kim, Jovina Goh, Zaven Panossian, Greg Gamble, Ian Holdaway, Andrew Gre. Pioglitazone in acromegaly - an open-label, prospective study. Clinical endocrinology. vol 77. issue 4. 2013-02-04. PMID:22512403. |
preclinical studies demonstrate that thiazolidinediones (tzds) decrease growth hormone (gh) and insulin-like growth factor-1 (igf-1) levels, suggesting that they might be effective treatments for acromegaly. |
2013-02-04 |
2023-08-12 |
Not clear |
| Renata S Auriemma, Rosario Pivonello, Maria Cristina De Martino, Giuseppe Cudemo, Ludovica F S Grasso, Mariano Galdiero, Ylenia Perone, Annamaria Cola. Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. European journal of endocrinology. vol 168. issue 1. 2013-02-04. PMID:23065994. |
treatment with gh receptor antagonist in acromegaly: effect on cardiac arrhythmias. |
2013-02-04 |
2023-08-12 |
Not clear |
| Claudia Giavoli, Eriselda Profka, Elisa Verrua, Cristina L Ronchi, Emanuele Ferrante, Silvia Bergamaschi, Elisa Sala, Elena Malchiodi, Andrea G Lania, Maura Arosio, Bruno Ambrosi, Anna Spada, Paolo Beck-Pecco. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. The Journal of clinical endocrinology and metabolism. vol 97. issue 11. 2013-01-25. PMID:22904173. |
effects of gh replacement in patients with gh deficiency (ghd) after a cure for acromegaly so far have been poorly studied, although its prevalence among acromegalic patients may reach the 60%. |
2013-01-25 |
2023-08-12 |
Not clear |
| Claudia Giavoli, Eriselda Profka, Elisa Verrua, Cristina L Ronchi, Emanuele Ferrante, Silvia Bergamaschi, Elisa Sala, Elena Malchiodi, Andrea G Lania, Maura Arosio, Bruno Ambrosi, Anna Spada, Paolo Beck-Pecco. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. The Journal of clinical endocrinology and metabolism. vol 97. issue 11. 2013-01-25. PMID:22904173. |
the aim of the study was to evaluate whether metabolic parameters and quality of life are improved by gh replacement in patients with prior acromegaly and severe ghd. |
2013-01-25 |
2023-08-12 |
Not clear |
| E Lin, T L Wexler, L Nachtigall, N Tritos, B Swearingen, L Hemphill, J Loeffler, B M K Biller, A Klibanski, K K Mille. Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clinical endocrinology. vol 77. issue 3. 2013-01-17. PMID:22315983. |
however, the effects of developing gh deficiency after definitive treatment of acromegaly are largely unknown. |
2013-01-17 |
2023-08-12 |
Not clear |
| Nicholas F Marko, Emily LaSota, Amir H Hamrahian, Robert J Wei. Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. Journal of neurosurgery. vol 117. issue 3. 2013-01-01. PMID:22725987. |
acromegaly, a syndrome of excess growth hormone (gh) secretion typically caused by a gh-secreting pituitary adenoma, reduces life expectancy by approximately 10 years when left untreated. |
2013-01-01 |
2023-08-12 |
Not clear |
| S N Boysan, F Kantarci, O Celik, I Mihmanli, N Gazioglu, Pinar Kadiogl. Atherosclerotic risk factors and premature atherosclerosis in acromegaly before and after 48 months of octreotide-LAR treatment. Angiology. vol 63. issue 7. 2012-11-19. PMID:22238353. |
in conclusion, premature atherosclerosis was demonstrated in active acromegaly patients probably as a consequence of insulin resistance and direct vascular effects of gh and/or insulin-like growth factor 1. |
2012-11-19 |
2023-08-12 |
Not clear |
| Emmanuel Somm, Nicolas Bonnet, Alberto Martinez, Philip M H Marks, Verity A Cadd, Mark Elliott, Audrey Toulotte, Serge L Ferrari, René Rizzoli, Petra S Hüppi, Elaine Harper, Shlomo Melmed, Richard Jones, Michel L Auber. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. The Journal of clinical investigation. vol 122. issue 9. 2012-11-19. PMID:22850878. |
we designed and tested a bont-derived targeted secretion inhibitor (tsi) targeting pituitary somatotroph cells to suppress growth hormone (gh) secretion and treat acromegaly. |
2012-11-19 |
2023-08-12 |
rat |
| Hideyuki Arita, Manabu Kinoshita, Satoru Oshino, Tetsuhiro Kitamura, Michio Otsuki, Soji Kasayama, Toshio Shimokawa, Iichiro Shimomura, Toshiki Yoshimine, Youichi Saito. Biological characteristics of growth hormone-producing pituitary adenomas are different according to responsiveness to thyrotropin-releasing hormone. The Journal of clinical endocrinology and metabolism. vol 97. issue 8. 2012-10-24. PMID:22569237. |
the paradoxical response of gh to trh in patients with acromegaly has been previously reported. |
2012-10-24 |
2023-08-12 |
Not clear |
| Nilanjan Sengupta, Uma Sinha, Keshab Sinha Roy, Sudipta Sah. Acromegaly without acral changes: A rare presentation. Indian journal of endocrinology and metabolism. vol 16. issue 3. 2012-10-02. PMID:22629521. |
acromegaly was proven by high level of serum insulin like growth factor-1 (igf-1) and elevated and nonsuppressed level of growth hormone (gh), with other hormonal profile being undisturbed. |
2012-10-02 |
2023-08-12 |
Not clear |
| Zdenko Killinger, Martin Kužma, Lenka Sterančáková, Juraj Paye. Osteoarticular changes in acromegaly. International journal of endocrinology. vol 2012. 2012-09-26. PMID:23008710. |
acromegaly is caused by hypersecretion of growth hormone (gh) and consequently of insulin-like growth factor-i (igf-1) due to pituitary tumor. |
2012-09-26 |
2023-08-12 |
Not clear |